SAGE Overview
Upcoming Projects (SAGE)

Don’t see a project related to the company you care about? Create your own!
Executed Projects (SAGE)

A Second View: Examining the potential of Sage217 in treating MDD ahead of the results from the WATERFALL study
Ticker: SAGE
Executed On: May 19, 2021 at 11:00 AM EDT 
Examining the potential of Sage217 in treating MDD ahead of the results from the WATERFALL study
Ticker: SAGE
Executed On: May 07, 2021 at 02:00 PM EDT 
A Second View: Examining the Depression Drug Development Landscape including SAGE217, AXS05, Rel1017, and esketamine
Tickers: SAGE, AXSM, JNJ, RLMD
Executed On: Apr 14, 2020 at 11:00 AM EDT 
Examining the Depression Drug Development Landscape including SAGE217, AXS05, Rel1017, and esketamine
Tickers: SAGE, AXSM, JNJ, RLMD
Executed On: Apr 10, 2020 at 03:00 PM EDT 
Edison will be hosting a call to discuss new CNS drugs including esketamine, SAGE547, and SAGE217.
Tickers: SAGE, AGN, JNJ
Executed On: May 11, 2017 at 03:00 PM EDT
Free Project 
Digesting the significance of SAGE547's success in its Phase 2 postpartum depression study
Ticker: SAGE
Executed On: Jul 29, 2016 at 12:45 PM EDT
Expired Projects (SAGE)

Analyzing Marinus’ Ganaxolone in treating Postpartum Depression, after its Phase 2 Magnolia and Amaryllis trials data
Tickers: MRNS, SAGE
Execute By: Aug 28, 2018
Upcoming & Overdue Catalysts (SAGE)

Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SAGE)

Phase 1 biomarker data of Sage Therapeutics' (SAGE) SAGE718 in Huntington's disease due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 
Phase 1 MAD data of Sage Therapeutics' (SAGE) SAGE324 in Essential tremor due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 
SAGE 547 May Not Go On Sale Until 2018 (Assuming FDA Approval; PDUFA Dec 19 2018)
Ticker: SAGE
Occurred on: Nov 20, 2018 
SAGE Expects NDA Filing for SAGE 547 2nd Half of 2017
Ticker: SAGE
Occurred on: Apr 23, 2018 
Phase 2 TopLine Data for SAGE217 in Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Apr 17, 2018 
Phase 2 OpenLabel Data Evaluating SAGE217 in Major Depressive Disorder Due H1 2017
Ticker: SAGE
Occurred on: Dec 07, 2017 
SAGE TopLine Phase 3 Data Evaluating SAGE547 in Moderate and Severe Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Nov 09, 2017 
Phase 2 OpenLabel Data Evaluating SAGE217 in Parkinson's Disease Due H1 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 
Phase 2 TopLine Data Evaluating SAGE217 in Essential Tremor Due H2 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 
EMA Scientific Advice for SAGE547 in Postpartum Depression Due H1 2017
Ticker: SAGE
Occurred on: Aug 03, 2017 
SAGE's First NMDA Program (SAGE 718) Could Enter Clinical Trials Mid2017
Ticker: SAGE
Occurred on: Apr 27, 2017 
Topline Data from Phase 2 ProofofConcept Trial of SAGE217 in Parkinson's Disease
Ticker: SAGE
Occurred on: Feb 13, 2017 
Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE217 in Mood Disorders
Ticker: SAGE
Occurred on: Dec 19, 2016 
SAGE Plans to Initiate Phase 2 Trials for SAGE 217 (Essential Tremors and Orphan Epilepsies) 2nd Half of 2016
Ticker: SAGE
Occurred on: Dec 13, 2016 
Sage Receives FDA Breakthrough Therapy Designation for SAGE547 for the Treatment of Postpartum Depression
Ticker: SAGE
Occurred on: Sep 06, 2016
Strategic Initiatives (SAGE)

Don’t see a strategic initiative related to the company you care about? Create your own!